Request the brochure

* Denotes Required Field

Theme: Discover the Latest Innovations in Science on Antibody Discovery, CGT, Immunotherapy, Drug Conjugates, Antibody Engineering, Machine Learning and Much More in China...

In the past few years, immune checkpoint inhibitors, such as PD-1, PD-L1, CTLA-4 mAb, CAR-T etc. have revolutionized treatment regimens for several cancers. Biologics have entered the center stage of drug discovery. As of February 2020, CGT products account for 12 percent of the industry’s clinical pipeline and at least 16 percent of the preclinical pipeline. As of Apr. 2021, over 100 antibody therapeutics have been approved.  

Looking at China, China’s Made in China 2025 identified biopharma industry as one of ten key industries to target. Today, the development of new-generation innovative biologics, such as ADCs and CGTs, is well underway. China is one of the leading nations in the development of cell and gene therapies and is the second largest in the world for CAR-T clinical trials. China's pharmaceutical industry was undertaking a critical transformation toward high-quality and innovation-focused development.

Meanwhile, China's biopharma industry, with growing applications of digital technology to biologics innovation, AI, and bioprocessing technology such as continuous bioprocessing, will grow the number of made in China innovative biologics in the globe market. Read more…

Snapshot of BIFT China 2022

  • Chinese market for Cell and Gene Therapies
  • Latest CAR T-cell technology developments
  • Commercialization of ATMP products in China
  • Manufacturing & clinical trials of novel immune cell therapy
  • High throughput characterization of antibody, AAV and cell therapy aggregates
  • Off-the-Shelf Immunotherapies for faster, cheaper & standardized therapies
  • Solid tumors treatment with CAR-NK, TIL, and TCR-T generation
  • Enhancing therapeutic efficacy of Cell Therapy in Solid Tumors
  • Next generation linkers and site specific technology
  • The CMC development of biologics for breakthrough designations
  • Smart biomanufacturing and process optimization
  • Innovative upstream, downstream processing and continuous processing
  • Sustainable manufacturing and scalability
  • Trends in Pharma 4.0 standards and China’s new drug development strategy
  • Novel CLD platform technologies and tools
  • Antibody informatics accelerated with AI or machine learning

Event Features

  • 800+ delegates representing leading antibody and CGT marketing players in China
  • 100+ attending organizations covering value chain in mAb and CGT industry
  • 50+ eminent speakers from top biotech, pharma, and academics
  • 70% on average attendees from primary market (biotech, research institutes, biopharma etc)
  • 60%+ attendees at company decision making and director level
  • 3 conferences at 1 location with 12 focused streams
Produced by
Media Partners